Information for the media and for our investors

Formycon Reports Its Nine-Month Figures For 2019

The company's group sales, including other earnings, as of September 30 of this year, amount to EUR 26.8 million while EBITDA was well-balanced and net result totaled around EUR -0.7 million. Formycon Group's stocks of liquid assets, including short-term receivables from deliveries and services as well as other assets are totaling EUR 29.2 million on the day of reporting.

Bioeq IP AG Exclusively Licenses US Marketing Rights For FYB201 To Coherus BioSciences, Inc.

Bioeq IP AG, the exclusive owner of the global commercialization rights of Formycon’s FYB201 has signed a license and development agreement with Coherus BioSciences, Inc. The US Biosimilar-specialist, headquartered in California, will exclusively market and distribute Formycon's biosimilar candidate to Lucentis® (FYB201) in the United States of America (US).

Formycon Announces Start of Phase I Clinical Trial With Ustekinumab Biosimilar Candidate FYB202

Formycon AG today announced the start of a Phase I clinical trial comparing the pharmacokinetics, safety, and tolerability of FYB202 and the reference product Stelara® (USA / EU). Dosing of study subjects started last week.

Formycon Publishes Half-Year Results for 2019

Formycon AG has today announced its financial results for the first half of 2019. With a Group turnover of Euro 17,2 million and a period result of Euro -0,7 million Formycon Group's commercial figures were as forcast.

Formycon Reports on Annual General Meeting 2019

Formycons shareholders followed the proposals of the Board of Management and the Supervisory Board and approved all resolutions proposed by the management with large majorities in each case.

Formycon Reports Further Course of Capital Measure

With the agreement dated June 26, 2019, Wendeln & Cie. KG, an asset management company of Mr. Peter Wendeln (anchor shareholder and long-standing member of the Supervisory Board of Formycon AG), acquired all rights from the certificate of subscription as well as the 577,397 shares in Formycon AG from the cash capital increase.

Formycon Publishes Figures for the First Quarter of 2019

The Group sales, including other earnings, as of March 31 of this year amount to EUR 9.5 million. Earnings before interest, taxes, depreciation and amortization (EBITDA) amounted to EUR 0.5 million. The operating result (EBIT) as well as the quarterly result totaled around EUR 0.2 Million. The reported sales revenues result from reimbursements for development work in the licensed-out projects or projects developed in partnership. For the 2019 fiscal year, revenues in the amount of approximately EUR 35.0 million are expected at the group level.

Formycon Reports Latest Status of Capital Increase

As of today, totaling EUR 5,000,000.00, have been paid to the company’s capital increase account. The signatory's debt contribution amounting to EUR 12,264,170.30 is therefore still outstanding. The shares have so far not been delivered due to the as yet unsettled payment.

Formycon Reports Successful 2018 Financial Year

The Group's turnover rose compared to last year (Euro 29 million) by 48 percent to around Euro 43 million, exceeding forecasts. The earnings before interest, tax, depreciation and amortization on fixed and immaterial assets (EBITDA) were Euro 8 million (previous year Euro -0.8 million), which is significantly higher than last year’s figure.

Formycon Announces News on Development Portfolio

Formycon has published news on its development portfolio. The FDA submission of FYB201 is expected for the beginning of the fourth quarter of this year. The submission to the European Medicines Agency (EMA) is scheduled for the first quarter of 2020. Also significant progress have been achieved with FYB202 and FYB203.

Strategic Investor M&H Equity AG Subscribes Cash Capital Increase of Euro 17.3 Million

The Swiss company M&H Equity AG from Heerbrugg in the Canton of St. Gallen is a strategic investor with a long-term investment horizon. The funds acquired from the capital increase should be used primarily to develop the company’s own biosimilar products and further increase the value of the pipeline.

Formycon Places Cash Capital Increase of EUR 17.3 Million with Institutional Investor

Strategic investor M&H Equity AG subscribes for a cash capital increase of € 17,264,170.30 million in the context of a private placement with an issue price of 29.90 EUR per share. The funds acquired from the capital increase will be used primarily to develop the company’s own biosimilar products, particularly FYB205.

Formycon Releases Updates on Development Programs and Milestones

For FYB201, new data from the recently completed COLUMBUS-AMD phase III trial in patients with neovascular age-related macular degeneration (nAMD) are available.

Formycon Reports Nine-Month Figures for 2018

The turnover of the Formycon group increased significantly compared with the first nine months of 2017.

Formycon Reports Financial and Operating Results for the First Half Year of 2018

Formycon AG has revealed impressive results for the first half of 2018 both in the development of its product candidates and its business figures. Key milestones were reached on project FYB201, a biosimilar candidate for Lucentis®* (ranibizumab).

Formycon Appoints Development and Production Expert Thomas Siklosi to the Advisory Board

The former board member of Rentschler Biopharma SE is a renowned biotech manager and expert of biologics and biosimilars

Formycon with Significant Growth in Turnover and Earnings in the First Quarter of 2018

Formycon has significantly improved its revenue and earnings in the first quarter of 2018 compared to the same period of the previous year.

Formycon With Successful 2017 Financial Year

Formycon has ended the 2017 financial year successfully and has once again significantly advanced the development of its product candidates.

Formycon and Bioeq Achieve Important Milestone: Biosimilar Ranibizumab Candidate FYB201 Shows Efficacy Comparable to the Reference Product in Phase III Study

In the COLUMBUS-AMD Trial the primary endpoint has been achieved, thus confirming comparable efficacy between FYB201 and the reference medicinal product Lucentis® in patients with neovascular age-related macular degeneration (nAMD).

Biosimilar Candidate FYB201 Shows Efficacy Comparable to the Reference Product in Phase III Study

According to an interim result, the primary endpoint has been achieved in the COLUMBUS-AMD phase III trial, which is intended to demonstrate the efficacy, safety and immunogenicity of FYB201 and the reference medicinal product Lucentis® in patients with neovascular age-related macular degeneration (nAMD).

Formycon Ranks 7th in the Financial Times List of Europe’s 1000 Strongest-Growing Companies

Formycon has ranked 7th in the FT1000 list compiled by the highly respected business newspaper the Financial Times and data provider Statista, making it the only biotech company to appear in the top ten.

Formycon and Aristo Pharma are Founding a Joint Venture for the Development of FYB202

Formycon and Aristo Pharma GmbH, a company of the Struengmann-Group, have formed a joint company for the continued development of FYB202, Formycon's biosimilar candidate for Stelara® (ustekinumab).

Formycon Reports Operating and Financial Results for the Third Quarter of 2017

Formycon has again progressed well with the further development of its four biosimilars and confirmed the Euro 25 million sales target for whole of 2017.

Formycon Sets Course for the Future and Confirms Management Board Members until mid-2022

The Supervisory Board of Formycon has extended the appointments of Dr. Carsten Brockmeyer, board member and CEO, and Dr. Nicolas Combé, board member and CFO, until June 30, 2022.

Formycon Reports Financial and Operating Results for the First Half Year of 2017

Formycon has accomplished a successful first half year in 2017. Phase III clinical trial of FYB201 is continuing to progress as planned, the implementation of development cooperation agreement for FYB202 is anticipated for second half of the year

Formycon signs term sheet for development of FYB202 and executes capital increase

Formycon plans to enter into a co-investment arrangement for its biosimilar candidate FYB202 and aims for a participation of up to 30% in worldwide marketing proceeds.

Formycon Publishes Figures for the First Quarter of 2017

The commercial performance of Formycon has again advanced as planned in the first quarter of 2017 and the development of its four biosimilar projects has progressed as expected.

Formycon Announces Details of Further Pipeline Product: FYB202 is a Biosimilar Candidate for Stelara® (ustekinumab)

Formycon has announced details of a further product from its development pipeline: FYB202 is a biosimilar candidate for Stelara®* (ustekinumab).

Formycon With Successful 2016 Financial Year

Formycon has ended the 2016 financial year successfully and significantly advanced the development of its product candidates.

Formycon Plans Change in New SME Stock Exchange Segment “Scale”

Formycon plans, with effect from March 1, 2017, to switch to Deutsche Börse AG’s new stock exchange segment “Scale” for small and medium-sized enterprises (SMEs).

Focus magazine lists Formycon as growth champion repeatedly

Formycon has been named "growth champion 2017" in the category "Chemistry and Pharma" by the news magazine Focus. In the overall ranking, Formycon took second place.

Formycon Makes Good Progress in First Nine Months of 2016

In the first nine months of the 2016 financial year, Formycon has further advanced the development of its drug candidates.

Formycon Wins Award from Stifterverband for Innovative Strength

Formycon has been awarded the Research Seal by the Stifterverband in recognition of its innovative research and development work. With this award, the organization is acknowledging the company’s dedication to the development of biosimilars.

Formycon Reports First Half 2016 Financial and Operating Results

The development of Formycon’s biosimilar candidates has progressed well during the first half of 2016. The company announced this update as it unveiled its 2016 half-year figures.

Formycon Expands Board and Appoints Pharma Top Manager Dr. Stefan Glombitza as Chief Operating Officer

Dr. Stefan Glombitza will join Formycon on October 1, 2016 and add his strengths to the Management Board. He will in future act as Chief Operating Officer (COO), focusing especially on the company's operational development activities

Formycon CEO Dr. Carsten Brockmeyer once again honored as one of the world’s most influential people in the medicines industry

Dr. Carsten Brockmeyer, CEO of Formycon AG, has again been chosen as one of the world’s top 100 most influential people in the pharmaceutical sector by the trade magazine “The Medicine Maker”

Formycon Publishes Figures for the First Quarter of 2016

The first quarter of 2016 has been successful for Formycon both in operational and financial terms. On the furthest-progressed development project FYB201, a biosimilar candidate for Lucentis®*, the first patient was enrolled in February of this year in the phase III study

Formycon ends 2015 fiscal year with successful results

Formycon has ended the 2015 financial year with both operational and financial success. In the last year, Formycon has made great strides with the initiation of the clinical Phase III study involving the biosimilar candidate FYB201 (ranibizumab) in particular.

Formycon discloses details on second pipeline product – FYB203 is a biosimilar for Eylea® (aflibercept)

Formycon AG has announced details on the second biosimilar product which is jointly developed with Santo Holding GmbH. FYB203 is a biosimilar candidate for Eylea® (aflibercept).

Formycon and bioeq enroll first patient in pivotal phase III study with biosimilar ranibizumab (FYB201)

Formycon AG, Munich, and bioeq GmbH, Holzkirchen, have enrolled the first patient in their clinical Phase III study involving FYB201, Formycon’s biosimilar version of Lucentis®

Formycon appoints biotech expert Professor Johannes Buchner to the Advisory Board

Formycon appoints Johannes Buchner, professor in Biotechnology at the Technical University of Munich, and President of the German Society for Biochemistry and Molecular Biology (GBM), to its Advisory Board

Formycon files multiple patent applications for the pharmaceutical formulation and delivery of intraocular VEGF antagonists

Formycon today announced that it has filed already three patent applications relating to the formulation and intraocular delivery of VEGF antagonists.

Formycon announces results for first nine months of 2015

Formycon has announced a significant increase in its revenue for the first nine months of this year, thus continuing on its path of profitable growth.

Global strategic partners bioeq and Formycon initiate pivotal phase III clinical trial with their Lucentis® biosimilar

Formycon AG, Munich, Germany, and bioeq GmbH, Holzkirchen, Germany, announced the initiation of a pivotal Phase III clinical trial with FYB201, an investigational biosimilar ranibizumab (Lucentis®)

Formycon announces positive financial results for first half of 2015

Formycon has closed the first half of its fiscal year 2015 with successful financial results. Consolidated revenue for the period ending June 30, 2015, was EUR 9.8 million. Net income for the six-month period was EUR 1.53 million.

Formycon AG receives favorable scientific advice from U.S. Food and Drug Administration for its partnered biosimilar candidate FYB201

Formycon AG has received a scientific advice letter from the U.S. Food and Drug Administration (FDA) regarding the preclinical and clinical development program for FYB201, the first biosimilar product candidate to emerge from its development pipeline, following the receipt of similarly favorable scientific advice from the European Medicines Agency (EMA) in December 2014.

Results announced for 1Q 2015, forecast raised for full-year 2015

In the first quarter of 2015, Formycon reported consolidated revenues of EUR 3.0 million. Based upon the recently announced successful signing of a partnership deal for FYB203, the company has raised its full-year forecast for fiscal year 2015, which it now expects to end with positive EBITDA.

Formycon AG signs licensing agreement for its FYB203 biosimilar

Under the agreement, Santo Holding will assume responsibility for, and the costs of, all further development activities, production and marketing of the Formycon biosimilar drug. Based on sales projections, the agreement is expected to yield Formycon total cumulative revenue well over the hundred million euro mark.

Carsten Brockmeyer belongs to the top 20 most influential people in the Global ‘Medicine Maker Power List’ 2015

He appears on the list alongside global leaders from the industry, including CEOs, Nobel Prize winners, and many other celebrated scientists from the pharmaceutical world.

Reappointment of board member Dr. Nicolas Combé

The Supervisory Board of Formycon AG has unanimously voted to extend the executive board appointment of Dr. Nicolas Combé, the co-founder of the company who has served with distinction as its chief financial officer since May 5, 2010.

Formycon AG successfully completes capital increase from approved capital

Proceeds from the share placement in the gross amount of EUR 11,115,960.00 will flow entirely to the company and are to be used to advance and expand the company’s biosimilar development programs in accordance with its plans, thus further strengthening the market position which Formycon has already achieved.

Formycon Group announces preliminary results for fiscal year 2014

Formycon AG has reported its preliminary consolidated financial results for fiscal year 2014, with sales revenue and other income totaling EUR 12.67 million (prior year: EUR 0.41 million). EBITDA for the year was EUR 1.94 million (prior year: - EUR 6.64 million), while net income came in at EUR 0.86 million (prior year: - EUR 7.74 million).

Formycon AG announces successful GMP inspection and the start of US FDA scientific advice procedure for its out-licensed biosimilar FYB201

This achievement is another important step in Formycon’s preparation of the pivotal phase III study of clinical testing for its first biosimilar candidate (FYB201).

Formycon AG moves planned start of pivotal phase III study for its first biosimilar product (FYB201) forward to 3Q 2015

For Formycon AG, the favorable response to its proposed plan for clinical studies means a significant shortening of its development and approval schedule.

Formycon AG releases nine-month figures for 2014

For the first nine months of 2014, the company posted revenues of EUR 8.98 million (2013: EUR 0.33 million). Its operating profitability likewise improved markedly, with EBITDA of EUR 2.64 million for the period from January through the end of September.

Formycon AG announces its results for the first half of 2014

In the first half of 2014, Formycon AG recorded a turnover of 7.4 million euros (2013: 0.2 million euros). The company's EBITDA amounted to 3.2 million euros in the first half of 2014 (first half of 2013: -3.0 million euros). Overall, the company expects to achieve positive EBITDA for the business year 2014.

Formycon AG commences development of its third product, seeing this as confirmation of its pioneering position in the “third wave” of biosimilar drugs

These products will be part of the so-called “third wave” of biosimilars, referring to the major, multi-billion-dollar blockbuster drugs created through biotechnology for indications in the areas of ophthalmology, autoimmune...

Formycon AG announces financial results of fiscal year 2013 and first quarter results of fiscal year 2014

For the first quarter of this year, Formycon AG has reported strong top-line and bottom-line growth, with revenue of EUR 5.832.904 compared to EUR 7.886 in the prior-year period.

Formycon AG: Strong partner increases marketing potential for the first biosimilar development project

Increased marketing potential for Formycon's first biosimilar FYB201 gives reason to expect a greater turnover share for Formycon.

Formycon AG appoints top US pharmaceuticals manager Bernhard Hampl to the Advisory Board

Over the past 20 years, Dr. Bernhard Hampl was a successful CEO in large American generics companies such as EON LABS Inc. and later Sandoz US, which after fusion of the two companies became America's second-largest manufacturer...

Formycon AG: Licensing out of the first biosimilar development project already enables extension of the product pipeline as of 2014

Formycon sets course for long-term alignment as a global biosimilar developer. Dr. Carsten Brockmeyer, one of the world's leading biosimilar experts, joined the board of directors. In addition Formycon appointed Dr. Gerhard Schaefer, former Head of Global Product and Business Development at Sandoz International, and Simon Sturge, previously Corporate Senior Vice President at Boehringer Ingelheim, to the advisory board.

Formycon AG signs first biosimilar licensing agreement with Santo Holding GmbH

Munich – Formycon AG today announced the signing of an exclusive, worldwide licensing agreement with Santo Holding GmbH, owned by the well noted German pharmaceutical investors Andreas and Thomas Strüngmann, granting rights to the first biosimilar drug of Formycon’s development pipeline.

Formycon AG successfully completes capital increase

Successful placement of shares among international institutional investores and family offices. The gross proceeds to the company of EUR 9,43 will be used to fund further product development activities.

Formycon AG today has announced the appointment of Gerhard Schaefer and Simon Sturge to Formycon’s Advisory Board

Gerhard Schaefer graduated with a Ph.D. in Chemistry from Stuttgart University. During his more than 30 years in the generic pharmaceutical industry, he held increasing senior management positions in development, quality assurance / control and business development at Azupharma, Knoll, Stada, HEXAL and Sandoz.